Blueprint Medicines Corp expected to post a loss of $1.66 a share - Earnings Preview

Blueprint Medicines

30/04/2024 18:25

* Blueprint Medicines Corp  BPMC.OQ   BPMC.O  is expected
to show
a rise in quarterly revenue when it reports  results on May 2
for the period ending March 31 2024
    * The Cambridge Massachusetts-based  company is expected to
report
a 27.1% increase in revenue to $80.434 million from $63.29
million a year ago, according to the mean estimate from 15
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Blueprint Medicines Corp
is
for a loss of $1.66 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 3
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 0.3%
in the last three months. ​
    * Wall Street's median 12-month price target for Blueprint
Medicines Corp is $100.00​, above​ its last closing price
of $93.10. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -2.06       -2.04      -1.82     Beat    10.8
 Jan. 1 2023   -2.33       -2.37      -2.20     Beat    7.1
 Jan. 1 0001   -2.54       -2.54      -2.19     Beat    13.8​
 Mar. 31 2023  -2.69       -2.67      -2.15     Beat    19.5
 ​​Dec.        -2.65       -2.65      -2.65     Met     0
 31 2022                                                
 Sep. 30 2022  -2.46       -2.49      -2.23     Beat    10.3​
 Jun. 30 2022  -2.25       -2.23      -2.68     Missed  -20.3
 Mar. 31 2022  -1.78       -1.86      -1.79     Beat    3.9
 This summary was machine generated April 30 at 17:25 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)